Department of Urology, Faculty of Medicine, Marmara University, İstanbul, Turkey.
Turk J Med Sci. 2023 Feb;53(1):206-210. doi: 10.55730/1300-0144.5575. Epub 2023 Feb 22.
Sacral neuromodulation (SNM) is a minimally invasive treatment that modulates spinal reflexes to regulate bladder, urinary sphincter, and pelvic floor and has successfully been used in the treatment of refractory voiding dysfunctions. The aim of this study was to present our experience with SNM in a tertiary referral center with the largest number of patients and review the safety and efficacy of the procedure.
A total of 42 patients with refractory lower urinary tract symptoms were included into the study. After an initial test period, patients who showed more than 50% improvement in their symptoms underwent the second stage of SNM. Twelve patients had overactive bladder (OAB), bladder pain syndrome/interstitial cystitis (BPS/IC) and 17 had urinary retention. The clinical success was examined during follow-up by voiding diary, urodynamics, and global response assessment.
Between February 2015 and December 2020, a total of 29 patients underwent stages I&II SNM procedures. The mean ages of patients in OAB/BPS group and retention group were 40 (37-57 years) and 35 (27-44 years), respectively. Mean follow-up time was at least 1 year. Overall, 58.5% success rate was observed in OAB, BPS/IC, and urinary retention groups. Global response assessment score in both groups increased significantly (p = 0.001). No statistically significant difference was found between success or failure rates when sex and age were variable parameters (p > 0.05).
SNM appears to be an effective and safe treatment option in restoring voiding dysfunctions in patients with refractory idiopathic and neurogenic voiding dysfunctions. Our initial series revealed favorable results; however, further studies with larger series and longer follow-up are needed.
骶神经调节(SNM)是一种微创治疗方法,通过调节脊髓反射来调节膀胱、尿道括约肌和盆底功能,已成功用于治疗难治性排尿功能障碍。本研究旨在介绍我们在一家拥有最多患者的三级转诊中心使用 SNM 的经验,并回顾该手术的安全性和有效性。
共有 42 例难治性下尿路症状患者纳入本研究。在初始测试期后,症状改善超过 50%的患者进行 SNM 的第二阶段。12 例患者患有膀胱过度活动症(OAB)、膀胱疼痛综合征/间质性膀胱炎(BPS/IC),17 例患者患有尿潴留。通过排尿日记、尿动力学和总体反应评估在随访期间检查临床疗效。
2015 年 2 月至 2020 年 12 月,共有 29 例患者接受了 I&II 期 SNM 手术。OAB/BPS 组和尿潴留组患者的平均年龄分别为 40(37-57 岁)和 35(27-44 岁)。平均随访时间至少为 1 年。总体而言,OAB、BPS/IC 和尿潴留组的成功率为 58.5%。两组的总体反应评估评分均显著增加(p=0.001)。当性别和年龄为变量参数时,成功率或失败率之间没有发现统计学上的显著差异(p>0.05)。
SNM 似乎是一种有效且安全的治疗选择,可以恢复难治性特发性和神经性排尿功能障碍患者的排尿功能。我们的初步系列结果令人满意;然而,需要进一步进行更大系列和更长随访的研究。